Want to see HK:1358 full AI Analyst Report?
1358 Stock Chart & Stats
HK$1.30
HK$0.02(2.06%)
At close: 4:00 PM EST
HK$1.30
HK$0.02(2.06%)
Day’s Range― - ―
52-Week RangeHK$0.97 - HK$1.63
Previous CloseN/A
Volume329.00K
Average Volume (3M)1.12M
Market Cap
HK$1.45B
Enterprise Value-HK$358.96M
Total Cash (Recent Filing)HK$1.81B
Total Debt (Recent Filing)HK$22.01M
Price to Earnings (P/E)13.8
Beta0.25
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.34%
Share Statistics
EPS (TTM)0.06
Shares Outstanding1,433,241,100
10 Day Avg. Volume754,100
30 Day Avg. Volume1,124,400
Financial Highlights & Ratios
PEG Ratio-0.51
Price to Book (P/B)0.44
Price to Sales (P/S)2.13
P/FCF Ratio12.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Conservative Balance SheetExtremely low leverage and a conservative balance sheet provide durable financial flexibility and downside protection. This supports capital allocation for R&D, dividends or M&A during cyclical pressures, and reduces refinancing risk, improving resilience over the next 2–6 months.
Historically Strong Gross Margins And GrowthSustained historical revenue growth and strong gross margins indicate durable product mix and pricing power in medical instruments. These structural strengths give margin buffer to absorb near-term cost pressure and support medium-term recovery in operating profit and competitive position.
Positive Operating And Free Cash Flow In FY2025Positive operating and free cash flow, even after weakening, indicate the business can internally fund operations and some investment. Reliable cash generation supports capital expenditure, working capital needs and shareholder distributions over the coming months compared with loss-making peers.
Bears Say
FY2025 Revenue Decline And Margin CompressionA tangible step-down in revenue and substantial margin compression signals weakening demand or pricing pressure that undermines earnings durability. Lower margins reduce reinvestment ability and returns, making near-term profit recovery and consistent free cash flow less certain.
Weaker And Volatile Cash Flow; Limited TransparencyDeclining and volatile free cash flow, coupled with missing cash-conversion metrics, reduces visibility into earnings quality and impairs forecasting. This variability elevates risk to dividend sustainability and capital spending plans over the medium term.
Low Returns On Equity; Inefficient Capital UseLow and declining ROE indicates the large equity base is not generating strong shareholder returns. Persistent low ROE limits long-term value creation and suggests capital allocation or operational efficiency issues that could constrain growth prospects.
PW Medtech Group Ltd. News
1358 FAQ
What was PW Medtech Group Ltd.’s price range in the past 12 months?
PW Medtech Group Ltd. lowest stock price was HK$0.97 and its highest was HK$1.63 in the past 12 months.
What is PW Medtech Group Ltd.’s market cap?
PW Medtech Group Ltd.’s market cap is HK$1.45B.
When is PW Medtech Group Ltd.’s upcoming earnings report date?
PW Medtech Group Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 21 days.
How were PW Medtech Group Ltd.’s earnings last quarter?
PW Medtech Group Ltd. released its earnings results on Mar 27, 2026. The company reported HK$0.021 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.021.
Is PW Medtech Group Ltd. overvalued?
According to Wall Street analysts PW Medtech Group Ltd.’s price is currently Overvalued.
Does PW Medtech Group Ltd. pay dividends?
PW Medtech Group Ltd. pays a Semiannually dividend of HK$0.02 which represents an annual dividend yield of 6.34%. See more information on PW Medtech Group Ltd. dividends here
What is PW Medtech Group Ltd.’s EPS estimate?
PW Medtech Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PW Medtech Group Ltd. have?
PW Medtech Group Ltd. has 1,433,241,100 shares outstanding.
What happened to PW Medtech Group Ltd.’s price movement after its last earnings report?
PW Medtech Group Ltd. reported an EPS of HK$0.021 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.009%.
Which hedge fund is a major shareholder of PW Medtech Group Ltd.?
Currently, no hedge funds are holding shares in HK:1358
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PW Medtech Group Ltd.
Operating within the People's Republic of China, PW Medtech Group Limited is an investment holding company primarily engaged in the medical device industry. The company specializes in the manufacturing and distribution of a diverse portfolio of medical consumables, including various types of infusion sets such as non-PVC, precision filter, and light-resistant models, alongside intravenous cannula products and insulin needles and pens. Beyond its core medical device activities, the group also provides property management services. Established in 1997, the company, previously known as Pyholding Limited, maintains its corporate headquarters in Beijing, China.
Technical Analysis
Shandong Weigao Group Medical Polymer Co
―
Modern Dental Group Limited
―
Shanghai Kindly Medical Instruments Co., Ltd. Class H
―
Angelalign Technology Inc.
―
OrbusNeich Medical Group Holdings Limited
―